<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03562481</url>
  </required_header>
  <id_info>
    <org_study_id>16-3106</org_study_id>
    <nct_id>NCT03562481</nct_id>
  </id_info>
  <brief_title>Clinical Trial Comparing Effectiveness of Buffered Versus Unbuffered Local Anesthetic in Children Ages 10-12 Years</brief_title>
  <official_title>Pilot Study: Comparison of Buffered 1% vs. Unbuffered 2% Lidocaine in Pediatric Subjects; Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Local anesthesia is an integral part of clinical pediatric dental practice, but it has
      challenges. It can be uncomfortable for children, and the risk of adverse events limits how
      much is used. Some evidence suggests benefits of buffering local anesthetics including equal
      effect with less pain on injection. These findings have not been replicated and validated
      among pediatric populations, creating a gap in the knowledge base. To address this knowledge
      gap and contribute to the evidence base on safety and efficacy of local anesthesia in
      pediatric dentistry, this investigation proposes to compare the anesthetic effects of
      buffered 1% lidocaine with those of unbuffered 2%, among children.

      The specific aims of this investigation are to determine differences between buffered 1% and
      unbuffered 2% lidocaine (both with 1:100,000 epinephrine) used for inferior alveolar nerve
      block (IAN) anesthesia, in the following domains:

        1. Pain experience on injection, time to onset following the administration, and time to
           recovery [subjective]

        2. Blood lidocaine levels 15 minutes following the administration and duration of pulpal
           anesthesia [objective]

      Null Hypotheses:

        1. No difference exists in anesthetic effectiveness for pulpal anesthesia after intraoral
           IAN block between buffered 1% Lidocaine with 1:100,000 epinephrine as compared to
           unbuffered 2% Lidocaine with 1:100,000 epinephrine.

        2. No differences exist in peak blood lidocaine levels, pain on injection, time to lip
           numbness, and duration of anesthesia between the two drug formulations.

      Randomized subjects will be injected orally for bottom jaw anesthesia, with 3cc of buffered
      1% lidocaine (30mg) 1:100,000 epinephrine or 3cc unbuffered of 2% lidocaine (60mg) 1:100,000
      epinephrine. The injectable volume of the buffered formulation will include 0.3cc of 8.4%
      sodium bicarbonate.

      One faculty member in the Department of Pediatric Dentistry at the University of North
      Carolina (UNC) School of Dentistry will administer the drugs in the Pediatric Dentistry
      clinic. The same clinician will administer injection to the same subjects at both visits.
      Clinicians and subjects will not know which drug formulation is given at which appointment.

      A clinician will measure the level of discomfort on injection, how long it takes for the lip
      to be numb, how long it takes for the first molar tooth in that area to be numb, how long it
      takes the local anesthetic to wear off, and how much of the anesthetic is in the blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2018</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Study subjects will serve as their own controls in this crossover AB/BA study design which is uniform within sequences (groups, i.e. AB/BA, of order of drug formulation administration), uniform within periods (equal time between administration of alternating drug formulations), and balanced (equal number of subjects within each study arm).
The randomization will be performed to the type of drug given first, using a balanced randomization (half subjects buffered, half unbuffered) implemented with SAS software routines. During the first session, each subject will receive an IAN block with the first randomly assigned anesthetic formulation using the Halstead technique. At least a week later, substantially longer than the elimination half-life of the drug lidocaine (1.5-2hr), local anesthetic injections will be done using the alternate local anesthetic formulation.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Pain Scores Following Injection</measure>
    <time_frame>Within 10 minutes of injection</time_frame>
    <description>Perceived pain on injection, self-reported verbally using a Likert scale from 1-10, with lower numbers corresponding to less pain (1 = &quot;no pain,&quot; 10 = &quot;worst pain imaginable&quot;). Lower scores reflect a lesser degree of pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Time to Lower Lip Numbness Following Injection</measure>
    <time_frame>Up to 30 minutes following injection</time_frame>
    <description>Time in minutes beginning immediately following injection to patient-reported lip numbness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Serum Lidocaine Concentration at 15 Minutes Post Injection</measure>
    <time_frame>One blood draw taken 15 minutes following injection</time_frame>
    <description>Blood Lidocaine Level (mcg/mL) as measured in 10cc venous blood, taken 15 minutes following injection. Blood assayed for serum lidocaine levels with a Sciex TripleTOF liquid chromatography- mass spectrometry (LC-MS) equipped with a C18 Hypersil (10mm x 2.1mm, 3.0Î¼m).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Time to Baseline Lip Sensation</measure>
    <time_frame>Within 24 hours following injection</time_frame>
    <description>Response in minutes from injection to when lip is no longer numb, as self reported by patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Respond to Cold Stimulus (Positive/Negative) Prior to Injection</measure>
    <time_frame>5 minutes prior to injection</time_frame>
    <description>Response to experiencing sensation to cold stimulus on permanent molar tooth prior to injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Respond to Cold Stimulus (Positive/Negative) 30 Minutes Following Injection</measure>
    <time_frame>30 minutes following injection</time_frame>
    <description>Response to experiencing sensation to cold stimulus on permanent molar tooth 30 minutes following injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Respond to Cold Stimulus (Positive/Negative) 60 Minutes Following Injection</measure>
    <time_frame>60 minutes following injection</time_frame>
    <description>Response to experiencing sensation to cold stimulus on permanent molar tooth 60 minutes following injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Respond to Cold Stimulus (Positive/Negative) 90 Minutes Following Injection</measure>
    <time_frame>90 minutes following injection</time_frame>
    <description>Response to experiencing sensation to cold stimulus on permanent molar tooth 90 minutes following injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Respond to Cold Stimulus (Positive/Negative) 120 Minutes Following Injection</measure>
    <time_frame>120 minutes following injection</time_frame>
    <description>Response to experiencing sensation to cold stimulus on permanent molar tooth 120 minutes following injection</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Anesthesia, Local</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Buffered Anesthetic, then Unbuffered Anesthetic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unbuffered Anesthetic, then Buffered Anesthetic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Buffered Lidocaine 1:100,000 Epinephrine</intervention_name>
    <description>A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.</description>
    <arm_group_label>Buffered Anesthetic, then Unbuffered Anesthetic</arm_group_label>
    <arm_group_label>Unbuffered Anesthetic, then Buffered Anesthetic</arm_group_label>
    <other_name>Xylocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% Unbuffered Lidocaine 1:100,000 Epinephrine</intervention_name>
    <description>A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.</description>
    <arm_group_label>Buffered Anesthetic, then Unbuffered Anesthetic</arm_group_label>
    <arm_group_label>Unbuffered Anesthetic, then Buffered Anesthetic</arm_group_label>
    <other_name>Xylocaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 10-12 years

          -  American Society of Anesthesiologists (ASA) Class I (Healthy)

          -  Body Weight: the Interquartile Range (IQR) 33-60Kg for subject ages

          -  Have ability to speak and read English

          -  Willingness to participate in two sessions

          -  No history of adverse reaction to dental anesthetic

          -  Have bilateral, disease/symptom-free mandibular first molars present

        Exclusion Criteria:

          -  Allergy to lidocaine class of anesthetic drugs

          -  Local anesthetic drug use in past week

          -  Current symptomatic teeth or oral mucosa

          -  ASA II or above (including asthma)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Y Lee, DDS,MPH,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC-Chapel Hill School of Dentistry, Pediatric Dentistry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC School of Dentistry</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <results_first_submitted>June 4, 2020</results_first_submitted>
  <results_first_submitted_qc>June 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2020</results_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy pediatric volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB) and executes a data use/sharing agreement with UNC.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>9 to 36 months following publication</ipd_time_frame>
    <ipd_access_criteria>Investigators who propose to use the data must have approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB) and must execute a data use/sharing agreement with UNC.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03562481/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1: Unbuffered Anesthetic, Then Buffered Anesthetic</title>
          <description>Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. 1% After one week minimum washout period, subjects will then receive an injection with Buffered Lidocaine 1:100,000 Epinephrine.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2: Buffered Anesthetic, Then Unbuffered Anesthetic</title>
          <description>Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence 1: Unbuffered Anesthetic, Then Buffered Anesthetic</title>
          <description>Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.</description>
        </group>
        <group group_id="B2">
          <title>Sequence 2: Buffered Anesthetic, Then Unbuffered Anesthetic</title>
          <description>Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.5" spread="0.5"/>
                    <measurement group_id="B2" value="10.9" spread="0.9"/>
                    <measurement group_id="B3" value="11.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Response to Cold Testing</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Negative Response to Cold Testing at Baseline</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive Response to Cold Testing at Baseline</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Scores Following Injection</title>
        <description>Perceived pain on injection, self-reported verbally using a Likert scale from 1-10, with lower numbers corresponding to less pain (1 = &quot;no pain,&quot; 10 = &quot;worst pain imaginable&quot;). Lower scores reflect a lesser degree of pain.</description>
        <time_frame>Within 10 minutes of injection</time_frame>
        <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Buffered Anesthetic</title>
            <description>Subjects being administered the Buffered Anesthetic received an injection with 3cc 1% Buffered Lidocaine 1:100,000 Epinephrine. for a single IAN block using the Halstead technique.
1% Buffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
          <group group_id="O2">
            <title>Unbuffered Anesthetic</title>
            <description>Subjects being administered the Unbuffered Anesthetic received an injection with 3cc of 2% Unbuffered Lidocaine with 1:100,000 Epinephrine for a single IAN block using the Halstead technique.
2% Unbuffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores Following Injection</title>
          <description>Perceived pain on injection, self-reported verbally using a Likert scale from 1-10, with lower numbers corresponding to less pain (1 = &quot;no pain,&quot; 10 = &quot;worst pain imaginable&quot;). Lower scores reflect a lesser degree of pain.</description>
          <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.9"/>
                    <measurement group_id="O2" value="3.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of variance for a 2x2 crossover study implemented using the pkcross routine of Stata 16.1, accounting of sequence and period effects.</non_inferiority_desc>
            <p_value>0.38</p_value>
            <p_value_desc>The threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Analysis of variance for a 2x2 crossover study implemented using the pkcross routine of Stata 16.1, accounting of sequence and period effects.</method_desc>
            <param_type>F statistic</param_type>
            <param_value>0.80</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Time to Lower Lip Numbness Following Injection</title>
        <description>Time in minutes beginning immediately following injection to patient-reported lip numbness</description>
        <time_frame>Up to 30 minutes following injection</time_frame>
        <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Buffered Anesthetic</title>
            <description>Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
1% Buffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
          <group group_id="O2">
            <title>Unbuffered Anesthetic</title>
            <description>Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.
2% Unbuffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time to Lower Lip Numbness Following Injection</title>
          <description>Time in minutes beginning immediately following injection to patient-reported lip numbness</description>
          <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.3"/>
                    <measurement group_id="O2" value="4.4" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of variance for 2x2 crossover study using the pkcross routine of Stata 16.1 and accounting for sequence and period effects.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence was defined as a non-statistically significant difference.</non_inferiority_desc>
            <p_value>0.28</p_value>
            <p_value_desc>The threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANOVA</method>
            <param_type>F statistic</param_type>
            <param_value>1.21</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Serum Lidocaine Concentration at 15 Minutes Post Injection</title>
        <description>Blood Lidocaine Level (mcg/mL) as measured in 10cc venous blood, taken 15 minutes following injection. Blood assayed for serum lidocaine levels with a Sciex TripleTOF liquid chromatography- mass spectrometry (LC-MS) equipped with a C18 Hypersil (10mm x 2.1mm, 3.0Î¼m).</description>
        <time_frame>One blood draw taken 15 minutes following injection</time_frame>
        <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Buffered Anesthetic</title>
            <description>Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
1% Buffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
          <group group_id="O2">
            <title>Unbuffered Anesthetic</title>
            <description>Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.
2% Unbuffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Serum Lidocaine Concentration at 15 Minutes Post Injection</title>
          <description>Blood Lidocaine Level (mcg/mL) as measured in 10cc venous blood, taken 15 minutes following injection. Blood assayed for serum lidocaine levels with a Sciex TripleTOF liquid chromatography- mass spectrometry (LC-MS) equipped with a C18 Hypersil (10mm x 2.1mm, 3.0Î¼m).</description>
          <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
          <units>mcg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.5" spread="127.9"/>
                    <measurement group_id="O2" value="600.2" spread="497.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of variance for 2x2 crossover study using the pkcross routine of Stata 16.1 adjusting for perio and sequence effects.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence was defined based on statistical significance in the cross-over ANOVA.</non_inferiority_desc>
            <p_value>0.003</p_value>
            <p_value_desc>This is adjusted for period and sequence effects and is statistically significant at the p&lt;0.05 level.</p_value_desc>
            <method>ANOVA</method>
            <param_type>F statistic</param_type>
            <param_value>11.1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Time to Baseline Lip Sensation</title>
        <description>Response in minutes from injection to when lip is no longer numb, as self reported by patient.</description>
        <time_frame>Within 24 hours following injection</time_frame>
        <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Buffered Anesthetic</title>
            <description>Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
1% Buffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
          <group group_id="O2">
            <title>Unbuffered Anesthetic</title>
            <description>Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.
2% Unbuffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time to Baseline Lip Sensation</title>
          <description>Response in minutes from injection to when lip is no longer numb, as self reported by patient.</description>
          <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218" spread="59.6"/>
                    <measurement group_id="O2" value="241" spread="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence was determined based on the statistical significance of the Wilcoxon signed-rank test.</non_inferiority_desc>
            <p_value>0.33</p_value>
            <p_value_desc>The threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>Sign test</method>
            <method_desc>Wilcoxon signed-rank test</method_desc>
            <param_type>Z score</param_type>
            <param_value>-0.996</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Respond to Cold Stimulus (Positive/Negative) Prior to Injection</title>
        <description>Response to experiencing sensation to cold stimulus on permanent molar tooth prior to injection</description>
        <time_frame>5 minutes prior to injection</time_frame>
        <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Buffered Anesthetic</title>
            <description>1% Buffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
          <group group_id="O2">
            <title>Unbuffered Anesthetic</title>
            <description>2% Unbuffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Respond to Cold Stimulus (Positive/Negative) Prior to Injection</title>
          <description>Response to experiencing sensation to cold stimulus on permanent molar tooth prior to injection</description>
          <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Negative Response to Cold Testing at Baseline</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive Response to Cold Testing at Baseline</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence was determined based on the statistical significance of the chi square test.</non_inferiority_desc>
            <p_value>0.37</p_value>
            <p_value_desc>The threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Chi-square test</param_type>
            <param_value>0.81</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Respond to Cold Stimulus (Positive/Negative) 30 Minutes Following Injection</title>
        <description>Response to experiencing sensation to cold stimulus on permanent molar tooth 30 minutes following injection</description>
        <time_frame>30 minutes following injection</time_frame>
        <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Buffered Anesthetic</title>
            <description>Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
1% Buffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
          <group group_id="O2">
            <title>Unbuffered Anesthetic</title>
            <description>Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.
2% Unbuffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Respond to Cold Stimulus (Positive/Negative) 30 Minutes Following Injection</title>
          <description>Response to experiencing sensation to cold stimulus on permanent molar tooth 30 minutes following injection</description>
          <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Negative Response to Cold Testing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive Response to Cold Testing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stuart-Maxwell test of marginal homogeneity implemented with the symmetry routine in Stata 16.1</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence was defined based on statistical significance in the symmetry test.</non_inferiority_desc>
            <p_value>0.65</p_value>
            <p_value_desc>The threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>Sruart-Maxwell symmetry test</method>
            <param_type>Chi-square test</param_type>
            <param_value>0.20</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Respond to Cold Stimulus (Positive/Negative) 60 Minutes Following Injection</title>
        <description>Response to experiencing sensation to cold stimulus on permanent molar tooth 60 minutes following injection</description>
        <time_frame>60 minutes following injection</time_frame>
        <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Buffered Anesthetic</title>
            <description>Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
1% Buffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
          <group group_id="O2">
            <title>Unbuffered Anesthetic</title>
            <description>Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.
2% Unbuffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Respond to Cold Stimulus (Positive/Negative) 60 Minutes Following Injection</title>
          <description>Response to experiencing sensation to cold stimulus on permanent molar tooth 60 minutes following injection</description>
          <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Negative Response to Cold Testing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive Response to Cold Testing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of symmetry or marginal homogeneity (Stuart-Maxwell) implemented with the symmetry routine in Stata 16.1.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence was defined based on significance in the symmetry test.</non_inferiority_desc>
            <p_value>0.71</p_value>
            <p_value_desc>The threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>Sruart-Maxwell symmetry test</method>
            <param_type>Chi-square test</param_type>
            <param_value>0.14</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Respond to Cold Stimulus (Positive/Negative) 90 Minutes Following Injection</title>
        <description>Response to experiencing sensation to cold stimulus on permanent molar tooth 90 minutes following injection</description>
        <time_frame>90 minutes following injection</time_frame>
        <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Buffered Anesthetic</title>
            <description>Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
1% Buffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
          <group group_id="O2">
            <title>Unbuffered Anesthetic</title>
            <description>Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.
2% Unbuffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Respond to Cold Stimulus (Positive/Negative) 90 Minutes Following Injection</title>
          <description>Response to experiencing sensation to cold stimulus on permanent molar tooth 90 minutes following injection</description>
          <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Negative Response to Cold Testing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive Response to Cold Testing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of symmetry (marginal homogeneity, Stuart-Maxwell) implemented using the symmetry routine in Stata 16.1.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence was defined based on statistical significance in the symmetry test.</non_inferiority_desc>
            <p_value>0.32</p_value>
            <p_value_desc>The threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>Sruart-Maxwell symmetry test</method>
            <param_type>Chi-square test</param_type>
            <param_value>1.00</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Respond to Cold Stimulus (Positive/Negative) 120 Minutes Following Injection</title>
        <description>Response to experiencing sensation to cold stimulus on permanent molar tooth 120 minutes following injection</description>
        <time_frame>120 minutes following injection</time_frame>
        <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Buffered Anesthetic</title>
            <description>Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
1% Buffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
          <group group_id="O2">
            <title>Unbuffered Anesthetic</title>
            <description>Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.
2% Unbuffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Respond to Cold Stimulus (Positive/Negative) 120 Minutes Following Injection</title>
          <description>Response to experiencing sensation to cold stimulus on permanent molar tooth 120 minutes following injection</description>
          <population>One participant did not complete the second intervention and was excluded from the data analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Negative Response to Cold Testing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive Response to Cold Testing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of symmetry (marginal homogeneity, Stuart-Maxwell) implemented using the symmetry routine in Stata 16.1.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence was defined based on the statistical significance of the symmetry test.</non_inferiority_desc>
            <p_value>0.26</p_value>
            <method>Sruart-Maxwell symmetry test</method>
            <param_type>Chi-square test</param_type>
            <param_value>1.29</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Following randomization through the end of Intervention 2, up to approximately 8 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Buffered Anesthetic</title>
          <description>1% Buffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.</description>
        </group>
        <group group_id="E2">
          <title>Unbuffered Anesthetic</title>
          <description>2% Unbuffered Lidocaine 1:100,000 Epinephrine: A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jessica Lee, DDS, MPH, PhD</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>9195373955</phone>
      <email>jessica_lee@unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

